fasudil has been researched along with Familial Primary Pulmonary Hypertension in 9 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Familial Primary Pulmonary Hypertension: Familial or idiopathic hypertension in the PULMONARY CIRCULATION which is not secondary to other disease.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ruan, HY | 1 |
| Zhang, YG | 1 |
| Liu, R | 1 |
| Jasińska-Stroschein, M | 1 |
| Owczarek, J | 1 |
| Łuczak, A | 1 |
| Orszulak-Michalak, D | 1 |
| Jiang, H | 1 |
| Guan, RJ | 1 |
| Wang, HY | 1 |
| Toba, M | 1 |
| Alzoubi, A | 1 |
| O'Neill, KD | 1 |
| Gairhe, S | 1 |
| Matsumoto, Y | 1 |
| Oshima, K | 1 |
| Abe, K | 1 |
| Oka, M | 2 |
| McMurtry, IF | 2 |
| Jiang, X | 1 |
| Wang, YF | 1 |
| Zhao, QH | 1 |
| Jiang, R | 1 |
| Wu, Y | 1 |
| Peng, FH | 1 |
| Xu, XQ | 1 |
| Wang, L | 1 |
| He, J | 1 |
| Jing, ZC | 1 |
| Mouchaers, KT | 1 |
| Schalij, I | 1 |
| de Boer, MA | 1 |
| Postmus, PE | 1 |
| van Hinsbergh, VW | 1 |
| van Nieuw Amerongen, GP | 1 |
| Vonk Noordegraaf, A | 1 |
| van der Laarse, WJ | 1 |
| Yu, YP | 1 |
| Huang, XM | 1 |
| Raja, SG | 1 |
| Gupta, V | 1 |
| Gupta, N | 1 |
| Shaik, IH | 1 |
| Mehvar, R | 1 |
| Nozik-Grayck, E | 1 |
| Komatsu, M | 1 |
| Ahsan, F | 1 |
2 reviews available for fasudil and Familial Primary Pulmonary Hypertension
| Article | Year |
|---|---|
[Progress in pharmacotherapy of pulmonary arterial hypertension in children].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Bosentan; Calcium Channel Blockers; Child; Epoprosten | 2012 |
Evaluation of clinical efficacy of fasudil for the treatment of pulmonary arterial hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cardiovascular System; Disease Models, Anima | 2012 |
2 trials available for fasudil and Familial Primary Pulmonary Hypertension
| Article | Year |
|---|---|
[Acute effects of intravenous fasudil with different dosage on patients with congenital heart defects and severe pulmonary arterial hypertension].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Familial Primary Pulmonary Hypertension; Heart | 2018 |
Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: a randomized, controlled, crossover study.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Inhalation; Adolescent; Adult; Cross- | 2014 |
5 other studies available for fasudil and Familial Primary Pulmonary Hypertension
| Article | Year |
|---|---|
The beneficial impact of fasudil and sildenafil on monocrotaline-induced pulmonary hypertension in rats: a hemodynamic and biochemical study.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cholesterol, HDL; Drug Therapy, Combination; | 2013 |
[Fasudil reverses monocrotaline-induced pulmonary hypertension in rats].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Familial Primary Pul | 2013 |
Temporal hemodynamic and histological progression in Sugen5416/hypoxia/normoxia-exposed pulmonary arterial hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiogenesis Inhibitors; Animals; Familial Primary Pu | 2014 |
Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Animals; Antihypertensive Agent | 2010 |
Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1,2-Dipalmitoylphosphatidylcholine; Aerosols; Alkalin | 2013 |